G protein-coupled receptors (GPCRs) are the largest signaling family in the genome, serve an expansive array of functions, and are targets for Ϸ50% of current therapeutics. In many tissues, such as airway smooth muscle (ASM), complex, unexpected, or paradoxical responses to agonists/antagonists occur without known mechanisms. We hypothesized that ASM express many more GPCRs than predicted, and that these undergo substantial alternative splicing, creating a highly diversified receptor milieu. Transcript arrays were designed detecting 434 GPCRs and their predicted splice variants. In this cell type, 353 GPCRs were detected (including 111 orphans), with expression levels varying by Ϸ900-fold. Receptors used for treating airway disease were expressed lower than others with similar signaling properties, indicating potentially more effective targets. A disproportionate number of Class-A peptide-group receptors, and those coupling to G q/11 or Gs (vs. Gi), was found. Importantly, 192 GPCRs had, on average, five different expressed receptor isoforms because of splicing events, including alternative splice donors and acceptors, novel introns, intron retentions, exon(s) skips, and novel exons, with the latter two events being most prevalent. The consequences of splicing were further investigated with the leukotriene B4 receptor, known for its aberrant responsiveness in lung. We found transcript expression of three variants because of alternative donor and acceptor splice sites, representing in-frame deletions of 38 and 100 aa, with protein expression of all three isoforms. Thus, alternative splicing, subject to conditional, temporal, and cell-type regulation, is a major mechanism that diversifies the GPCR superfamily, creating local recepteromes with specialized environments.
G
protein-coupled receptors (GPCRs) represent the largest superfamily of receptors in the human genome. They are expressed on every cell and carry out an extensive array of biologic signaling. These include receptors for vision and smell, neurotransmission, and thousands of endocrine, autocrine and paracrine functions throughout the body. Critical GPCR circuits have been identified in central nervous system, cardiovascular, gastrointestinal, pulmonary, endocrine, and renal disease (reviewed in ref. 1) , resulting in enhanced understanding of the pathologic basis of disease, new diagnostics, and new drug targets. Indeed, it has been estimated that Ϸ50% of pharmaceuticals are directed at GPCRs or their immediate downstream signaling events (2, 3) . There are several well recognized phenomena in GPCR signaling events, at both the in vitro and clinical levels, which have revealed a complexity beyond that initially expected. One issue has been the recognition that one receptor can regulate another through any number of heterologous mechanisms (4, 5) . This ''cross-talk'' appears to be necessary for the cell to integrate the large number of GPCR signaling events underway at any given time (6, 7) . Thus, the complement of receptors expressed on a cell, even those that do not appear to be directly involved with a pathway, can be a determinant of the cellular response to a given GPCR. Extensive heterogeneity in GPCR signaling has also been observed between individuals that is not readily resolved by physiologic setting or disease state. This interindividual variability in GPCR function, which may be responsible for disease risk or modification and altered response to therapy, has led to the notion of heterogeneity of either structure or expression of GPCRs within the human population. And indeed, quantitative measurements of GPCR expression and/or function in otherwise matched individuals typically reveal as much as 10-fold variability (8) . Similarly, common polymorphisms of GPCRs with functional implications have been identified, which appear to associate with some, but not all, of this variability (9) . Another mechanism that introduces diversity of expression or function is alternative mRNA splicing, giving rise to several ''isoforms'' of a receptor. The identification and characterization of alternatively spliced genes within the group of known and orphan GPCRs have not been delineated, so the extent of diversity imposed by this mechanism within this important superfamily of signaling modules is unknown.
In the airways, GPCRs expressed on smooth muscle regulate airway contraction and relaxation and have been extensively studied in regard to asthma pathogenesis and treatment (10) . Local increases in endogenous agonists acting at histamine, leukotriene, prostaglandin, muscarinic, thromboxane, and other GPCRs result in markedly enhanced bronchial hyperresponsiveness to contraction, leading to airway constriction. Other receptors, such as the ␤ 2 -adrenergic receptor (␤ 2 AR), appear to oppose constriction or evoke relaxation (10) , and thus airway smooth muscle (ASM) GPCRs have represented important targets for therapeutic agents, both agonists and antagonists, in asthma treatment. Nevertheless, a large body of pharmacologic data reveals complex, contradictory, or paradoxical responses of ASM GPCRs, bringing into question the role of certain receptors or pathways in smooth muscle pathophysiology and the potential utility of novel drugs targeting members of this superfamily. We hypothesized that ASM expresses many more GPCRs than predicted, and that these undergo frequent alternative splicing, resulting in unexpected receptor isoforms and thus creating a highly diversified receptor milieu. isolated and analyzed by using expression microarrays that provide for resolution of transcripts produced from the same locus by alternative splicing. The overall expression level per GPCR can be determined by using probes monitoring the classic ''nonspliced'' form. The arrays used here contain probes that monitor a total of 434 GPCR genes. The expression results from cultured ASM cells derived from five individuals are provided in supporting information (SI) Dataset S1. A total of 353 GPCR genes had statistically significant expression levels, defined as a 2-fold signal over background, and all such signals had Bonferroni-corrected P values of Ͻ10 Ϫ4 . Of interest, because they are targets for current pharmacologic therapy in obstructive lung disease, are the M 3 -muscarinic receptor (CHRM3) and ␤ 2 -adrenergic receptor (␤ 2 AR, ADRB2). Knowledge of expression of these ''benchmark'' therapeutic targets places into perspective expression results from other GPCRs, because they may relate to function or suitability as new drug targets. Antagonists to the former receptor are potent blockers of bronchoconstriction, whereas agonists acting at the ␤ 2 AR are the most efficacious bronchodilators known. Yet, both of these were among the lower-expressing GPCRs in ASM (Ϸ100-fold lower than the highest expressors), suggesting an unrecognized complement of receptors in this cell type that may be involved in pathogenesis of airway obstruction or may be new therapeutic targets. Among all significantly expressed GPCRs, expression varied by as much as Ϸ900-fold. Of the 353 receptors that were expressed, 111 were orphan GPCRs. Receptors were stratified by class (11) and by the major G proteins to which they couple based on published studies or by modeling techniques. As expected, the expressed GPCRs were dominated by members of Class A, which accounted for 72% of the nonorphan receptors. Within this class, the group of peptide receptors was most prevalent (60%), followed by the amine receptors (22%). The remainder of the Class A receptors were primarily of the hormone, prostanoid, and nucleotide families. The majority of non-Class A receptors were Class B secretin-like receptors. Examples of the heterogeneity of GPCRs expressed in human ASM and the relationship between G protein-coupling and expression level are shown in Fig. 1 . G q / 11 -and G s -coupled receptors were the most prevalent in human ASM (Fig. 1 ). This appears to be independent of the level of receptor expression, because the number of detected receptors which couple to G q / 11 and G s is similar in all expression quartiles, and greater than the number of detected G i / o -coupled receptors.
Diversity of GPCR Expression Due to Alternative Splicing in Human
ASM. The number of GPCRs with potential splice events that were identified in silico amounted to 252 of the 434 GPCR genes, representing a total of 1,500 events. Probe sets on the array were designed to detect each specific splicing event using the strategy depicted in Fig. S1 . Alternative splicing events of GPCR genes detected in human ASM are shown in Fig. 2 classified by event type. The data from individual GPCR splicing events from these cells are provided by sample in Dataset S2. A specific variant can be further assessed as to event-type, location within the gene of the splice event(s), and splice-site scores from the frequency matrix (12) in Dataset S3. Of the 252 potentially alternatively spliced GPCR genes, 192 had one (or more) alternative isoforms, with a total of 967 events detected. Exons and exon(s) skip events were the most common in ASM (Fig. 2) . Of note, these two categories should be considered similar, because the difference lies in which sequence has been selected as the reference (Fig.  S1 ). Of the Ϸ600 potential novel exons, Ϸ50% were expressed in ASM, which represented the smallest percentage of detected vs. probed events. A somewhat higher percentage was found for exon skip, alternative splice donor, and alternative splice acceptor events, and particularly so for the less-common novel intron and intron retention events. There was no apparent relationship between ''wild-type'' expression levels and the occurrence of a particular splicing event. That is, these events occurred regardless of the degree of overall expression of a given GPCR gene.
Three Expressed Forms of the Leukotriene B4 Receptor Due to Alternative Splicing. A select group of 30 GPCRs was chosen for further study based on high, intermediate, and low levels of expression, and their known relevance to ASM signal transduction (Table 1) . Overall expression levels within this group of genes (taking into account all variants) differed by up to Ϸ400-fold. Of the 30 genes selected for further analysis, 13 had no evidence of alternative splicing, whereas the remaining 17 genes contained 70 splicing events. Of these, 39 events were identified where novel exons or exon extension events were present and led to additional sequence in the alternatively spliced transcripts. Thirty-eight of these events were found to be significantly expressed above background, whereas one event was not statistically significant. In contrast, 31 events were found to consist of exon skip events or exon truncations, where splicing activity led to a loss of sequence. Twenty-four of these events were found to be significantly above background, whereas seven were not found to be expressed. From this set of expressed events, 17 were selected for validation by RT-PCR. The final list represented a variety of splice events (alternative donor and acceptor sites, novel introns, and novel and skipped exons), with multiple categories of supporting evidence for the event (sequences from mRNAs, ESTs, and RefSeqs). Primers were specifically designed for capturing spliced isoforms or were specifically targeted to amplify only the longer isoform ( Fig. S2 and Table S1 ). Data from the high-affinity leukotriene B 4 receptor (13) (LTB4R, also denoted LTB4R1 and BLT1, GenBank accession no. NM181657) showed several potential splicing events (Table 2 , Fig. 3 ) and was further explored to elucidate the ramifications of this diversification mechanism with a relevant signaling pathway in ASM. LTB4R has four splice events that were monitored on the array, and two were unequivocal, as determined from RT-PCR followed by sequencing. The two validated events, the alternative donor and acceptor sites, are illustrated in Fig. S2 . Both events were identified as part of the same transcript, so primers were designed to amplify the variant and the reference form of the transcript (primers are indicated in Fig. 3 ; F19 and R19 amplify both the reference and the variant, whereas F20 and R20 amplify only the reference). Amplicons were pooled, and bands were purified, cloned, and sequenced to verify the sequence structure for each variant. Slightly different variants were found in the 5ЈUTR but generated sequences that had exactly the same coding region as the reference sequence. Two additional variants contained a deletion of part of the 5ЈUTR and 5Ј-coding sequence (Fig. 3) ; the junction sequences Genes marked with an asterisk showed no evidence of splicing; mean signal and mean BG (background) represent intensity dye-normalized values, which were calculated as described in Methods. P values are Bonferroni corrected for the number of comparisons. Fig. 3 . Genomic organization and identification of potential splice variants in the LTB4R gene. A schematic diagram for LTB4R is illustrated approximately to scale to indicate the exons and introns for the reference LTB4R gene and three splice variants that were detected. The location of RT-PCR primers is indicated and was used to isolate amplicons that verified the sequences for each variant. The sequences were aligned to the genome and UTR and coding regions are indicated. LTB4R-AS1 has lost 39 aa internal of the coding region, whereas LTB4R-AS2 lost the initial 100 N-terminal aa.
for both of these variants were identical (Fig. 4A) . This resulted in a translated protein lacking the first 100 aa (LTB4R-AS2 in Fig. 4B ) compared with the reference protein. Another variant was found (Fig. 3 , clones A03 and A06), with alterations in the coding region distinct from the previous clones. The distinct junction for this clone was identified and revealed the loss of a portion of the second exon. This loss from alternative splicing is in-frame and results in the exclusion of amino acids 43-81 of the protein (LTB4R-AS1, Fig. 4B ).
Transmembrane modeling (Fig. 5 A-C) reveals that LTB4R-AS1 lacks the second transmembrane domain and part of the 5Ј portion of the first extracellular loop. LTB4R-AS2 lacks the N terminus, first transmembrane domain, first intracellular loop, second transmembrane domain, first extracellular loop, and Ϸ8 aa from the 5Ј portion of the third transmembrane domain. To ascertain whether the LTB4R-AS1 and -AS2 receptor proteins, which lack 39 and 100 aa, are expressed on human ASM cells, Western blots were carried out with a polyclonal antibody directed to a peptide representing the third intracellular loop of the human LTB4R. As shown in Fig. 5D , the full-length receptor was identified at its predicted molecular mass of Ϸ38 kDa. Two other forms were also identified at the predicted molecular mass of the two shorter forms at Ϸ33 kDa (LTB4R-AS1) and Ϸ27 kDa (LTB4R-AS2). The wild-type and -AS2 forms were expressed at approximately equivalent levels, whereas the -AS1 form was Ϸ10-fold lower in expression compared with either of the other two.
Discussion
In the human genome, typical pre-mRNAs consist (on average) of 8 introns and 9 exons, spanning Ϸ27,000 nt (14) . RNA splicing at intron-exon boundaries provides for deletion of introns, resulting in mature exon sequence. Such splicing, performed by ribonucleoprotein complexes (spliceosomes), is subject to conditional, temporal, and cell-type-specific regulation, resulting in alternatively spliced transcripts and thus various isoforms of the expressed protein (reviewed in refs. [15] [16] [17] . Alternative splicing is one mechanism by which the number of expressed proteins is thought to exceed the number of genes in the human genome. Thus, considerable structural diversity of expressed proteins can be realized from alternative splicing of a single gene. In the current work, we identified and characterized the splice variants of the GPCR superfamily because (i) it represents the largest family of signaling proteins in the genome, (ii) these receptors play a significant role in normal homeostasis and pathophysiology, and (iii) extensive efforts are underway to design agonists and antagonists for pharmacologic therapy. Genes encoding the majority of known and orphan GPCRs (not including those for smell or sight) were considered, and the cell-type interrogated was human ASM cells. This cell type was chosen because of its central role in the pathogenesis of airway obstruction in asthma and the known actions of GPCRs in ASM contraction, relaxation, and proliferation.
Of the 434 GPCRs monitored on the splice variant-specific array, 353 were detected over a wide range of expression levels in this cell type. This number of GPCRs is much greater than the Ϸ50 that were estimated to be expressed on human ASM based on evidence from pharmacologic and limited expression studies (10) . The several hundred GPCRs with relatively low expression levels should not be considered biologically insignificant, because this group includes the M 3 -muscarinic receptor, the ␤ 2 AR, and receptors for leukotrienes and prostanoids, all of which are important in the pathogenesis of obstructive lung disease or receptor-targeted therapy. Surveying the wild-type isoform expression levels of the G q -coupled receptors, which mediate bronchoconstriction, we noted expression of Ϸ150 receptors, extensive variation in levels of expression, and diversification via splice variants. These findings indicate potential new targets for antagonists and potential complexities because of multiple isoforms. For example, the CysLT1 receptor is currently a target for antagonists such as montelukast in the treatment of asthma. However, the orphan receptor GPCR 18, also predicted to be G q -coupled, was shown here to be expressed Ϸ4-fold higher than CysLT1 in ASM (Dataset S1) and may be an efficacious target for therapy, assuming that local levels of its endogenous ligand [N-arachidonylglycine (18) ] are increased in asthma. Similarly, the ␤ 2 AR, a G s -coupled receptor which is the target for ␤-agonists used to dilate the airways during bronchospasm, is expressed Ϸ25-fold lower than the orphan receptor GPCR 101, which is also predicted to be G s coupled. Thus, agonists to GPCR 101 could be more effective bronchodilators than ␤-agonists, or these agents could be coadministered to achieve maximal bronchodilation. Interestingly, GPCR 101 does not have the two consensus sequences for protein kinase A phosphorylation found in the ␤ 2 AR, which contributes to agonist-promoted desensitization of this receptor (19) . Thus, agonists for GPCR 101 may show less tachyphylaxis than ␤-agonists. Of the 353 GPCRs expressed on ASM, nearly two-thirds had in silico evidence for the potential to be alternatively spliced. Of these, 192 were found to express more than one isoform in this cell type, with a total of 967 splicing events detected in the superfamily. Of the spliced GPCRs, then, an average of approximately five different isoforms per receptor were expressed in ASM. This represents substantial diversity in a cell type where new pharmacologic agents are needed to control bronchospasm in asthma and chronic obstructive lung disease.
We chose the LTB4R for additional investigation because of its role in asthma and to emphasize the potential impact of splice variants on pathophysiology and treatment strategies. LTB 4 , like a number of other arachidonic acid metabolites, is increased in inflammatory states such as asthma, with elevated local levels in the airway (20) . The high-affinity receptor for LTB 4 , LTB4R, is well recognized as being expressed on neutrophils and other leukocytes (eosinophils, T-lymphocytes) and, when activated by its endogenous agonist, promotes leukocyte migration to the lung and participates in activation and degranulation (21) . To our knowledge, LTB4R expression on human ASM cells has not been previously identified. In recombinant expression systems, the receptor has been shown to couple to both G ␣i and G ␣q (22) . Given that G ␣q -coupled receptors act to constrict ASM, this suggests that LTB 4 could evoke bronchoconstriction directly, rather than via leukocyte recruitment. In guinea pig trachea, LTB 4 alone has been reported to have no effect on isometric contraction, but significantly enhances acetylcholine promoted contraction mediated by the G q -coupled M 3 -muscarinic receptor (23) . Other reports, though, have shown significant contraction of lung parenchymal strips by nanomolar concentrations of LTB 4 (24) . Some studies have concluded that LTB 4 antagonists have minor effects on leukocyte accumulation but decrease bronchial hyperreactivity (25, 26) , another showed decreased leukocyte recruitment but no effect on pulmonary function (27) , and another found that antigen-induced bronchoconstriction was decreased but eosinophil accumulation and acute bronchial hyperreactivity were unaffected (28) .
The discrepant bronchoconstriction effects from LTB4R antagonists may be due to the presence of splice variants of the receptor in ASM. We show here three forms of the transcribed LTB4R and two additional variations in the 5ЈUTR, which may alter the rate of transcription. The two splice variants involving the coding region lack domains that are likely necessary for LTB 4 binding to the receptor. However, both have intact G protein coupling domains (second and third intracellular loops) and thus may act as dominant-negative proteins during wild-type LTB4R signaling. Of note, traditional transcript-detection methods would have failed to identify the two alternatively spliced LTB4R transcripts, giving a false impression of the level of expression of the full-length receptor. Given that LTB4R-AS2 protein is expressed at approximately the same level as wild-type LTB4R, functional LTB4R expression is at least Ϸ1/2 that expected. And, if the splice variants act as dominant negatives, functional expression could be substantially lower or perhaps trivial. Development of LTB4R antagonists directed at the smooth muscle receptor would thus appear to have a low probability of therapeutic efficacy.
Taken together, the current results reveal an unexpectedly large number of receptors in the GPCR superfamily expressed in human ASM and extensive variability in structure because of alternative splicing leading to many receptor isoforms. The utility of these findings was explored in the LTB4R gene, where splicing events resulted in two previously unrecognized isoforms, which may explain discrepant results with antagonists for treating asthma. In regard to the superfamily, alternative splice donors and acceptors, skipped exons, novel exons, and novel and retained introns were all observed, leading to marked expansion of this signaling modality. Given that GPCRs are expressed on every cell type in the body and play prominent roles in signaling events in many diseases, consideration of this previously unrecognized diversity is necessary for understanding GPCR-related pathophysiology and therapeutic targets.
Methods
Bioinformatic Identification of Potential GPCR Splice Variants. An initial list of 434 GPCR gene representatives was determined by processing a set of nonviral and nonolfactory GPCR sequences obtained from public databases to a nonredundant set through genomic position (by alignment) clustering. These 434 representatives were compared with the exon structure of overlapping alignments at the same locus of the human genome in silico.
Sequences were aligned to the human genome (build 33) using BLAT (29) . RefSeq sequences met the criteria of 97% alignment identity and a minimum BLAT score of 200; in addition, EST alignments also had to include at least one splice junction, thereby having more than one exon, and Ͼ70% of the total sequence had to be represented. Orientation of the EST alignment and sequence was determined by comparison of consensus splice site scores of all splice junctions for the sequence performed in both sequence orientations. Overlapping sequences were compared by using genomic mapping coordinates, and differences in sequence content were determined through mathematical differences in the derived coordinates. Each event was given a unique identification number. For example, 106.008.001 indicates an event found in the 106th locus as found in the original gene list; the alignment was the eighth variant sequence checked in the locus, and this event was the first (001) event found in that variant sequence. Probe names consist of the event number with an underscore followed by a letter to indicate whether the probe is a common probe (A5 or A3), a long-form exon probe (B), a long-form junction probe (C or D), or a short-form junction probe (E) (Fig. S1) . Splice-site scores were calculated by using a frequency matrix from the AltExtron Database (www.ebi.ac.uk/asd/altextron/data/splicesitedists.html) (12) .
Probe Design and Microarrays for Splice Variant Identification.
A set of probes was synthesized for each event identified bioinformatically and was designed to obtain a common thermodynamic profile as described (30) . Probes directed against exon-exon junctions were limited to 24 bases to limit cross-reactivity from hybridization of half the junction probe to a single exon (30) . The microarrays were manufactured by Agilent Technologies with each probe printed in duplicate and randomly distributed on the microarray slide. Primary human ASM (bronchial) cells derived from five individuals were obtained from Clonetics and were maintained in monolayers in SMBM media (Clonetics). Cells at passages 3 or 4 were detached and total RNA prepared. (We are unaware of data suggesting that short-term culture alters the fundamental processes of splicing, but overall expression levels of genes, including GPCRs, could be affected by culture conditions.) Five micrograms of total RNA from each sample was labeled by using a random primed labeling protocol described by Xiang (31) with the following modifications: the final concentrations of dTTP and aadUTP were 250 M, instead of 300 and 200 M, respectively; the first-strand synthesis was not stopped with EDTA but directly hydrolyzed for 10 min at 65°C; after neutralization, the labeled material was purified by using the Rapid PCR purification system (Marligen) and eluted twice with 50 l of each of RNase-free water preheated to 65°C. For hybridization, sets of dye-swap experiments were performed with each sample using 2.5 g each of Cy3-and Cy5-labeled cDNA along with 40 g of herring sperm DNA (Invitrogen). The mixture was heated at 98°C for 3 min and then brought to room temperature for 5 min in the presence of 25 l of 10ϫ Control Targets from an in situ hybridization kit (Agilent Technologies). After addition of the 2ϫ hybridization buffer, the mixture was hybridized to the GPCR arrays at 65°C for 17 h. The arrays were washed by using a 60-mer oligo microarray processing protocol (Agilent), with washes of 5 min each. The arrays were scanned by using an Agilent Microarray Scanner. The images were analyzed with the Feature Extraction software, version 8.1 (Agilent Technologies), using the default settings. Dataset S2 contains probe level information from all 10 hybridizations (five samples processed in duplicate). Intensity dyenormalized values and processed background values are given for each probe (see Data Analysis and Modeling for details).
Data Analysis and Modeling. The mean signal and background values from the output files were used to produce datasets that were compared to determine probes significantly expressed over background. The dye normalization factor was calculated from values in the file for each probe/sample combination and multiplied by the background and mean signals to produce dye normalized values. To calculate gene level expression values, the median value from all ''A'' probes for each gene or locus was calculated (A1 and A2 were used for genes without splice events, A3 and A5 probes for genes with splice events, Dataset S1). The median data values were log 2 transformed, and a two-way ANOVA model was performed by using signal type (signal vs. background) and dye as a factor to generate Bonferroni-corrected P values for all probes to determine probes that were expressed significantly above background. Receptors were classified by their signaling to the three major classes of G protein: G i/o, Gs, and Gq/11, using the International Union of Pharmacology database (32) and literature searches. Predicted G protein-coupling specificity for unclassified orphan receptors was determined by a support vector machine and hidden Markov model using the program GRIFFIN (33) . Transmembrane spanning predictions were made by the TMHMM Server v2.0 (www.cbs. dtu.dk).
Western Blots. To detect expression of the LTB4R isoforms, a polyclonal antibody (Sigma) directed against a peptide representing the third intracellular loop of LTB4R was used in Western blots from whole-cell ASM lysates. Studies were performed with 40 g of protein and a primary antibody titer of 1:1,000 using methods described (4) .
